Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Insulin glargine
DATE: 23/06/2016
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
